GlobalData on MSN
Neurocrine’s Phase II MDD success raises analyst spirits
Analysts have high hopes for the depression drug, which would be the first in it class if it were to be approved.
OCD and BFRBs can look alike, but they’re not the same. Discover the similarities, important distinctions, and what they mean for treatment and recovery.
Transcranial magnetic stimulation and ketamine have been effective in treating depression. But when patients still struggle ...
Otsuka receive CRL from US FDA for sNDA of Rexulti in combination with sertraline to treat adults with post-traumatic stress disorder: Japan Monday, September 22, 2025, 10:00 Hrs ...
FDA denies approval for Rexulti in PTSD treatment, citing insufficient evidence despite clinical trials. Otsuka and Lundbeck plan next steps.
DelveInsight's Moderate-to-Severe Acute Pain Market Insights report includes a comprehensive understanding of current ...
Once you start taking antidepressants, it will take a long time before you can stop. Dr Sood suggests making sure the benefits outweigh the risks.
World Sleep and Psych Congresses showcase Jazz's leadership in sleep medicine Novel results from the Phase 4 DUET trial ...
Understanding how drugs interact with their molecular targets at the atomic level is central to modern drug discovery.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback